DBVT
DBV TechnologiesDBVT
DBVT
About: DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Employees: 106
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
99% more capital invested
Capital invested by funds: $8.46M [Q4 2024] → $16.8M (+$8.37M) [Q1 2025]
0.26% less ownership
Funds ownership: 2.66% [Q4 2024] → 2.4% (-0.26%) [Q1 2025]
6% less funds holding
Funds holding: 18 [Q4 2024] → 17 (-1) [Q1 2025]
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7.25
33%
downside
Avg. target
$14.81
37%
upside
High target
$21
94%
upside
4 analyst ratings
3 positive
75%
0 neutral
0%
1 negative
25%
JMP Securities Jonathan Wolleben | 94%upside $21 | Market Outperform Reiterated | 26 Jun 2025 |
Goldman Sachs Rajan Sharma | 33%downside $7.25 | Sell Reinstated | 29 May 2025 |
HC Wainwright & Co. Andrew Fein | 48%upside $16 | Buy Maintained | 5 May 2025 |
JMP Securities Steven Delaney | 39%upside $15 | Market Outperform Maintained | 1 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal Investigator Additional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patch 250 μg in peanut-allergic children ages 1 – 3 years old. COMFORT Toddlers will enroll approximately 480 subjects at approximately 80 – 90 study centers across the U.S., Canada, Australia, UK and Europe.
Neutral
GlobeNewsWire
4 weeks ago
DBV Technologies to Participate in Upcoming EAACI Congress 2025
Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall.
Neutral
GlobeNewsWire
1 month ago
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company.
Neutral
GlobeNewsWire
1 month ago
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced today the filing of an addendum to the 2024 Universal Registration Document (the “Addendum”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). This Addendum provides an update to the Board of Directors' Corporate Governance Report to account for the exceptional compensation granted to the Chief Executive Officer by the Board of Directors during its meeting on April 30, 2025.
Negative
Zacks Investment Research
1 month ago
Are Medical Stocks Lagging DBV Technologies (DBVT) This Year?
Here is how DBV Technologies S.A. (DBVT) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
1 month ago
Are You Looking for a Top Momentum Pick? Why DBV Technologies S.A.
Does DBV Technologies S.A. (DBVT) have what it takes to be a top stock pick for momentum investors?
Positive
Zacks Investment Research
1 month ago
DBV Technologies (DBVT) Is a Great Choice for 'Trend' Investors, Here's Why
DBV Technologies (DBVT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Neutral
GlobeNewsWire
1 month ago
Combined General Meeting of June 11, 2025
Châtillon, France, May 15, 2025 Combined General Meeting of June 11, 2025 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on June 11, 2025, at 02:00 p.m. CEST (08:00 a.m EST) at the Company's headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France.
Neutral
GlobeNewsWire
2 months ago
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference
Châtillon, France, May 5, 2025 DBV Technologies to Participate in the Citizens JMP Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025, at 11:00am ET, in New York, NY. A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company's Investors website: https://dbv-technologies.com/investor-overview/events/ A replay will also be available on DBV Technologies' website for 90 days after the event.
Neutral
GlobeNewsWire
2 months ago
DBV Technologies Reports First Quarter 2025 Financial Results
Châtillon, France, April 30, 2025 DBV Technologies Reports First Quarter 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three months financial statements were approved by the Board of Directors on April 30, 2025.
Charts implemented using Lightweight Charts™